Early Phase 1 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part in clinical research voluntarily
- People aged between 18 and 65 years old
- People who were diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease) at least 6 months before the screening appointment
- People whose blood tests at screening show certain markers linked to SLE (called antinuclear antibody, anti-dsDNA antibody, and/or anti-Sm antibody)
- People whose SLE has returned after treatment or has not responded well enough to previous treatments
- People whose major organs (such as kidneys, liver, and heart) are functioning adequately at the time of screening
- People whose blood and other lab test results meet the specific levels required at screening
Who may not be able to join:
- People who have active infections, such as hepatitis or tuberculosis
- People who have other autoimmune diseases (conditions where the immune system attacks the body)
- People who have serious underlying health conditions, such as cancer or diabetes that is not well controlled
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial or within one year of receiving the study treatment (LCAR-AIO)
- People who have taken part in another clinical trial recently (confirm with trial site for the exact time frame, as the original criteria appear incomplete)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 85726808
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence, severity, and type of treatment-emergent adverse events (TEAEs); Incidence of dose-limiting toxicity (DLT); Pharmacokinetics in peripheral blood; Recommended Phase 2 Dose (RP2D) regimen finding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.